Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders....
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will ...
MB-105 in Patients With CD5 Positive T-cell Lymphoma
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymph...
A Study of Enasidenib in People With T-Cell Lymphoma
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look a...
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lympho...
Top Cities for Peripheral T-Cell Lymphoma Clinical Trials
Peripheral T-Cell Lymphoma clinical trials are recruiting across 24 cities. Here are the cities with the most active studies:
About Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas are a diverse group of aggressive non-Hodgkin lymphomas that develop from mature T-cells. They account for about 10-15% of all NHL cases. Treatment includes combination chemotherapy, stem cell transplant, and newer targeted agents.
Clinical trials are advancing new treatments for peripheral t-cell lymphoma. Currently, 6 studies are recruiting a combined 277 participants across the United States. Research is being conducted by 6 organizations including University of Michigan Rogel Cancer Center, University of Virginia, March Biosciences Inc and 3 others.
2026 Peripheral T-Cell Lymphoma Research Landscape
As of March 2026, the peripheral t-cell lymphoma clinical trial landscape includes 6 actively recruiting studies across 24 cities in the United States. These studies are collectively seeking 277 participants, with an average enrollment target of 46 per study.
Research is being led by 6 different organizations, including University of Michigan Rogel Cancer Center, University of Virginia, March Biosciences Inc, Yale University, Memorial Sloan Kettering Cancer Center, and 1 others.
Geographically, peripheral t-cell lymphoma trials are most concentrated in Boston, Massachusetts (6 trials); Tampa, Florida (2 trials); Durham, North Carolina (2 trials); New Haven, Connecticut (2 trials); New York, New York (2 trials) and 7 other cities.
Featured Peripheral T-Cell Lymphoma Studies
Highlighted recruiting studies for peripheral t-cell lymphoma, selected by enrollment size and research scope.
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidine to single agent drugs already determined effective in patients with PTCL. For the purposes of this study, the single a...
MB-105 in Patients With CD5 Positive T-cell Lymphoma
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Frequently Asked Questions About Peripheral T-Cell Lymphoma Clinical Trials
Are there peripheral t-cell lymphoma clinical trials near me?
Yes, there are 6 peripheral t-cell lymphoma clinical trials currently recruiting across 24+ cities in the United States, including Boston, Massachusetts; Tampa, Florida; Durham, North Carolina. Browse the studies above to find one at a location convenient for you.
How do I join a peripheral t-cell lymphoma clinical trial?
To join a peripheral t-cell lymphoma clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are peripheral t-cell lymphoma clinical trials free?
Yes, participation in peripheral t-cell lymphoma clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of peripheral t-cell lymphoma treatments are being studied?
Current peripheral t-cell lymphoma clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 6 research organizations.
Is it safe to participate in peripheral t-cell lymphoma clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov